Insulin Efsitora Alfa

Summary

Insulin Efsitora Alfa (CHEMBL5095357) is a phase-3 clinical-stage protein; indicated across 2 conditions including type 1 diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095357
Name	Insulin Efsitora Alfa
Type	Protein
Max phase	3

Also known as: Insulin efsitora alfa, LY-3209590, LY3209590, INSULIN EFSITORA ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 1 diabetes mellitus	3	MONDO:0005147	MONDO:0005147
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE1	10
PHASE3	5
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05275400	PHASE3	COMPLETED	A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
NCT05362058	PHASE3	COMPLETED	A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
NCT05462756	PHASE3	COMPLETED	A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
NCT05463744	PHASE3	COMPLETED	A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
NCT05662332	PHASE3	COMPLETED	A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
NCT03736785	PHASE2	COMPLETED	A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
NCT04450394	PHASE2	COMPLETED	A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
NCT04450407	PHASE2	COMPLETED	A Study of LY3209590 in Participants With Type 1 Diabetes
NCT02942914	PHASE1	COMPLETED	A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes
NCT03367377	PHASE1	COMPLETED	A Study of LY3209590 in Participants With Type 2 Diabetes
NCT03603704	PHASE1	COMPLETED	A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
NCT04276428	PHASE1	COMPLETED	A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
NCT04768842	PHASE1	COMPLETED	A Study of Two Different Formulations of LY3209590 in Healthy Participants
NCT04957914	PHASE1	COMPLETED	A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
NCT05596747	PHASE1	COMPLETED	A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
NCT05615532	PHASE1	COMPLETED	A Relative Bioavailability Study of LY3209590 in Healthy Participants
NCT06169982	PHASE1	COMPLETED	A Multiple Dose Study of LY3209590 in Participants With Type 2 Diabetes
NCT06362265	PHASE1	COMPLETED	A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).